This $4.82 Stock Will Skyrocket?

Folks, analysts believe that this $482 stock is set to skyrocket. Now, for context, analysts at big firms have been rushing to upgrade and rerate stock after stock after stock over the past week. And in some cases, their price targets are forecasting hundreds of percentage points of upside. Now, you may say, Charlie, why do we care what the analysts think? Well, there's a clear reason. You see, analyst ratings can often be a self-fulfilling prophecy. When any company gets rated high by a firm, oftentimes what happens is that company gets a ton of PR. That PR breeds attention. That attention breeds momentum. And that momentum breeds what? More momentum. And the more important the analyst firm, well, the more active managers use that analyst price target as a way to justify their position in the first place. And then if the stock goes down, what happens? Well, they say, "Look, it's just volatility. This big shot analyst firm said it's a good buy." But of course, the key with analyst price targets is simply making sure that you're aware of them before most of the move has happened. And so in today's video, I'm going to do my best to present you with the most aggressive, most standout, and most unique analyst price targets, forecasts, and reratings on Wall Street. And then for the main entre, we're going to break down one specific stock that stands out the most that's at about $4.82, one that Wall Street is projecting a more than double on. And then after all that, we've got our sponsored segment. And today's sponsored segment is on Soma Pharmaceuticals. Ticker symbol S N O A on the NASDAQ. This small healthcare company cracked a century old trade-off, an antiseptic that kills bacteria without damaging healthy tissue using the same molecule your own white blood cells produce. It has 23 FDA clearances product in CVS and Walmart and a market value amounting to a fraction of what it books in revenue every year. I'll break down the company and why you may want to put it on your radar and begin your due diligence. And as always, if you're the one taking the ultimate risk, you better be the one doing the ultimate frisk. Always do your frisky frisky before you take on any risky risky. Wise words. I believe that was a direct quote from Albert Einstein. Okay, let's start with Art Terrace, sticker symbol AIP. So, Arteras makes something you've never seen, but it's sitting inside almost every advanced chip that chipping right now. Now, when a designer is building an AI accelerator, they're building dozens of separate blocks that all have to talk to each other at enormous speed. We've been talking about a lot of ideas in regards to this problem, but this is another big one. The wiring that connects those blocks is called a network onchip. And Arcteras licenses that technology to the designers. It does not have to manufacture anything, which is a big overhead it doesn't have to worry about. It sells the blueprint and collects royalties on every chip that ships with its technology inside. That's quite the beautiful licensing model. Now, Roth Capital just started coverage on this company with a buy rating and a $40 price target. Shares closed Wednesday at $30.93, down some 3.6% on the day. So, the call sits now at about 29% above where the stock finished. Six analysts on Wall Street cover the company now with a strong buy consensus and a $38.50 average, roughly 24% higher than the current trading price. Now, this is one of the more modest predictions on this list. However, it's one that you definitely want to pay attention to because I believe you're going to see a rush to upgrade this price target specifically because the buildout is continuing to accelerate at such a massive degree. But why did this company just get an upgrade? Well, because the customer roster just got very serious, super serial. You see, AMD agreed to use Artteras' Flex Gen to handle high performance data transport inside its chiplets, powering AI across its entire product portfolio. So, this is a very beautiful anchor customer, having AMD as your anchor customer is quite beautiful. Annual contract value plus royalties hit $69.1 million, up 15% year-over-year and the highest the company's ever reported. remaining performance obligations rose 28% to 99.3 million also a record this number is basically backlog plus unpaid invoices they just call it RPO to make it confusing for you now this is big business every custom silicon program at every hyperscaler is a potential license here next bit deer started in Bitcoin mining and is now pivoting very aggressively into becoming an AI infrastructure player owns data centers across Singapore the US Bhutan Norway Finland Ethiopia and Canada And critically, it owns the power contracts underneath them. Those contracts were signed years ago for mining, but they're worth far more for hosting AI workloads. And this is a big business for every minor that's transitioning right now. On top of that, Bitier signs and manufactures its own hardware, the so-called seal miner line, rather than buying rigs from somewhere else. Now, Caner Fitzgerald, one of the biggest analyst firms on the street, upgraded the stock to overweight from neutral and raised its price target to $18 from the previous $15. against Wednesday's close of $116. That's a pretty big upside. It's about 63% of upside. Why the upgrade, though? Well, this company just signed a key collocation and services agreement for AI and high performance computing worth close to $5 billion, and this is a 16-year lease. Now, their analyst Brett Nolocks read is that the muted reaction tells you almost none of the pipeline is being valued yet. In his words, quote, "With the muted reaction in shares post deal announcement, very little, if any, of the pipeline is being priced in." And he's not alone. Needm took its target at $22 this week and B Riley sits at $23. Both roughly a double from here. The Wall Street average across 10 analyst is $2210, which is almost exactly 100% above Wednesday's close. Caner's 18 is actually the low end of the bullish range, but I wanted to start with that one because Caner is kind of because Caner tends to be very finicky with their price targets. They're saying 18. That's a conservative estimate. Next, E.L.F. Beauty. Ticker symbol ELF. E.L.F. built a cosmetics company on a simple idea. prestige quality formulations at mass market prices marketed almost entirely through social platforms instead of traditional advertising. It launches constantly moves faster than legacy beauty and and uses Tik Tok as a key distribution channel. So that's how it took share in color cosmetics. Then it ran the same play in skincare. Now it is doing hair care. Now if you look at what the analysts are saying, Bernstein upgraded E.L.F. to outperform from market perform and raised its price target to $113 from $60. That's an 88% somewhat increase in a single rating. This is actually the largest target move anywhere in this batch and this is going to get a lot of attention over the coming weeks and it implies a roughly 29% upside from today's close. But I think this is going to be another one where analysts start racing to upgrade this company because it is down so aggressively from its all-time highs at the same time where its business is firing on all cylinders with proof of concept. Analyst Kristen Rios's reasoning runs straight through the skincare playbook. E.L.F. Skin grew from 0.6% 6% market share in 2022 to 1.4% in 2026 across Neielson track channels. And that's a big jump in terms of overall market share. Rios thinks the same approach applied to hair care gets to roughly 0.9% share by 2029. Which if you do the math on this would translate to somewhere around 210 million in fully incremental annual net sales. A big deal and something that could cause a quite the rally rally toe in the stock price. Next we've got Kratos Defense Kos. Kratos builds the things that the Pentagon wants a lot of cheaply and fast. The first is unmanned systems, jet powered target drones and collaborative combat aircraft. The category the Air Force is counting on to fly alongside manned fighters at a fraction of the cost. The second is the Kratos government solutions which covers hypersonics, microwave electronics, and rocket propulsion. The company also makes its own small turbo jet and turboan engines which matters more than it sounds and engine supply has been the bottleneck strangling the entire cruise missile and drone industry. Kratos reported their second quarter results on Tuesday and beat on both lines. Revenue of $458.8 million against a 400 and 11.2 million estimate which is about an 11.6% beat and adjusted earnings of 21 cents against 15 cents expected a 38% beat. Now, in July, Kratos disclosed roughly $400 million in new Department of War money tied to hypersonic systems and other national security programs. It picked up a $156 million soul source contract from the National Nuclear Security Administration and $100 million prime award for a groundbased space domain awareness system. And it finished construction of its Indiana Payload integration facility for hypersonics ahead of schedule. Wall Street responded to this by rushing to upgrade the price targets. Piper Sandler's Clark Jeff moved Kratos to overweight from neutral with a $75 price target against Wednesday's close of $55.34 which implies about 36% of upside. His reasoning is specific and it's about visibility rather than valuation. In his words, "A number of items have changed over the last 6 months, giving him greater comfort on near-term growth with a clear bridge on how the mock TB hypersonic program, expended turbo jet and turboan production, and potential new tactical drone production contribute to the model over the next 12 months." He added that recent funding events and award activity increased his comfort in the pipeline of new revenue. Now, if you look at the analyst price targets, Piper Sandler was at $75, Noble Financials at $145, BTIG was at $104, Clear Street $86, and across 15 analysts, 14 rated as a buy and one as a hold with an average target of $96.79, about 75% above the close. And the stock is still down about 59% from its 52- week highs. Next, we've got Cororeweave, CRWV. Corweave rents out GPUs. The hyperscalers do a 100 things. Coreweave does one which means its data centers are purpose-built for AI workloads from the ground up rather than retrofitted from general purpose cloud. Truist upgraded the stock to buy from hold with a $126 price target. Shares closed Wednesday at $89 and some 89 which means this call is for the stock to go up about 40%. City came in on Wednesday at $142 and the most bullish number on the board is wait for it drum roll please. Boom boom boom boom boom boom. Cander Fitzgerald at $167. Then Piper Sandler started coverage at overweight with $151 price target. Consensus across 24 analysts though sits at 127 and.76 cents roughly 42% above the close. Now Piper says that Coree's master service agreements and its financing approach remove some of the financing risk that the market has misunderstood and that its engineering team drives genuine differentiation by lowering cost per token and enabling multicloud deployments. Their analyst, James Fish, sizes the GPU as a service market at roughly $18 billion today, growing past a h 100red billion by 2029, a pace he explicitly calls conservative. He also argues the Neo clouds undercut even the hyperscalers on cost by more than 40%. So if you believe his analysis, well, Coreweave is an obvious buy. Okay, now it's time for the stock of the hour. Satellogic, ticker symbol SATL. Satellogic builds its own satellites and then sells you time on them. That's their whole business model. And the vertical integration here is the point. You see folks, most Earth imaging companies either operate a fleet or manufacture the hardware. Satellogic does everything from building the satellites, delivering the finished imagery. Revenue comes in three ways. Asset monitoring for customers who want a specific place watched over time. Constellation as a service for governments that want dedicated capacity of their own and technical support for clients run an operations on satellic's technology. If an agriculture firm, for example, wants crop stress mapped across a growing region or a government wants eyes on a particular border crossing on a particular Tuesday, they task a satellite and get imagery back. The company's headquartered in Monteito, Uruguay and sales across Asia Pacific and North America. Now, Satlogic reported earnings today and they closed at about $4.82. After earnings came out, the stock went up aggressively and then went down below the close price. Who knows what it's going to be at by the time you watch this video. The most aggressive call on this name belongs to Michael Latimore of Northland Securities who carries an $11 price target on the stock about 128% above where the stock closed today. Across five analyst consensus is a strong buy with a $9.51 average. Still roughly 97% or 100% higher depending on where this is trading at when you watch this video. And every single Wall Street analyst covering it rates it as a buy. Why exactly would this company have such a high consensus? Well, because this is a key player in geospatial intelligence, which is a very important thing right now. You see, persistent overhead imaging went from something that's a nice to have to something that governments budget for every single year. And Satellic has a beautiful cost structure that lets it compete against many operators many times its size. Analysts are modeling a long-term growth rate for the business of 74%. And then last night, Satellogic put a number up that nobody was modeling, and I think you're going to see a rush to upgrade the stock even more. You see, revenue came in at $15.9 million. Analysts were looking for somewhere between $9.3 and $9.8 million. So, that is quite the beat. That's a beat of more than 60% and it's up 259% from the $4.4 million the company did in the quarter a year ago. Break it down by segment. Well, data and analytics, the imagery and constellation as a service side, went from 4 million to 7.1 million. Space Systems, which is Satalogic selling entire satellites, went from half a million dollars to 8.8 million. This is largely coming from government, by the way. And if you go over to operating income, it was positive 0.3 million. That's the first quarter of positive operating income in the company's history. Adjusted Ibata was positive 2.8 million, a 6.7 million swing from a 3.9 million loss a year ago. Also a first and the CEO called it the inflection point we have been building towards. So all good news and all a beautiful report. Now, on the operational side, Satellogic delivered the first satellite to Portugal's CIA program, and it signed a one-year deal worth more than $18 million with an international defense customer and expansion from trial to full deployment in under 6 months, and also signed a separate $12 million agreement to sell and fully transfer a commissioned in orbit satellite to a sovereign defense customer who has yet to be named. Now, their Merlin constellation, which is designed to remap the entire planet daily at 1 meter resolution, is on track for first launch in the fourth quarter of this year with with full operational capability in the first half of 2027. Management says it's fully funded by existing customer contracts and needs no additional capital to hit those milestones, which that's music to my ears. But if you actually look at their data, their balance sheet, the balance sheet has 112.8 million in cash, up from 94.4 million at year end, remaining performance obligations of $80.7 million with 45.8 8 million of that expected to convert to revenue inside 12 months. So, here I have a very well-run small company with a huge amount of analyst upside, a beautiful balance sheet, and a lot of catalyst to look forward to. That's why it deserve the number one spot on today's list. Anyways, let us know what your favorite stock is on today's list. Which one you're the most bullish on? We love hearing from you. Anyways, it's now time to go on to our sponsored segment. And today's sponsored segment is on Soma Pharmaceuticals, ticker symbol SNA, on the NASDAQ. This small healthcare company cracked a century old trade-off. An antiseptic that kills bacteria without damaging healthy tissue using the same molecule your own white blood cells produce. It has 23 FDA clearances product in CVS and Walmart and a market value amounting to a fraction of what it books in revenue every year. I'll break down the company and why you may want to put it on your radar and begin your due diligence. So, what is Sonoma Pharmaceuticals? Well, Sonoma is a healthcare company out of Boulder, Colorado. Built around a single platform technology called Microsan, a stabilized hypocchlorous acid. It manufactures at its own high-capacity plant in Guadalara, Mexico, runs its European commercial base out of the Netherlands, and sells into more than 55 countries, mostly through partners. The platform stretches across wound care, burn care, dermatology, eye care, animal health, and consumer skincare. And last fiscal year, the whole operation did $19.5 million in revenue. So, what's the market cap they're trying to fill? It starts with the chemistry. So stay with me for a second because everything else falls from it. Hypocchloric acid is not a synthetic invention. Your own white blood cells produce it. Whenever you have an open wound, while neutrfiles rush to the site and manufacture this exact molecule to kill bacteria. And because your body evolved to make it, it does the job without damaging the healthy tissue around it. That is the part that matters commercially because almost everything else in your medicine cabinet makes you choose. alcohol, hydrogen, peroxide, iodine, they all kill microbes and they all damage the tissue you are trying to heal. That trade-off has been the standing compromise in wound care for roughly a century. So the obvious question then becomes, well, okay, well, why is hypocchlorous acid not simply taken to the market? The answer is that it falls apart. Left in solution, it degrades into salt water. The commercial problem was never whether the molecule works. It was whether you could bottle it, ship it across an ocean, park it on a shelf for two years, and still have the same molecule when a nurse cracks it open. Stabilization is the barrier to entry. And that is what Sonoma spent two decades in a patent portfolio getting past. Meanwhile, the demand side moved on its own. Hypocchloric acid went from a hospital wound care product to a mainstream skincare ingredient. Facial sprays, acne treatments, itch and rash gels, which created a very specific opening. A lot of brands now want an HOCI product. Almost none of them have a stabilization process, a validated plant, or the clearances to sell one. Sonoma's argument is that it has all three, and that it is worth more as the company behind other people's products, then as one more brand fighting for its own shelf space. Now, what's the business model? The first is contract manufacturing. A partner arrives wanting an HOCI product. Soma formulates it, makes it in Guadalara, packages it under the partner's brand, and hands it back. That is how Medline wound cleanser happened last October. Medline being one of the largest medical product distributors in the country and it is how a new sensitive skin dermatology line launched under Person and Kov's Aquanil brand in March. The second is consumer retail again through partners. Sonoma's advanced burn relief hydrogel went nationwide in CVS and Walmart in March. A diaper rash hydrogel hit mass retail the year before. Acne products went into more than 12,200 stores in the UK through a major health and beauty chain. And the key structural point is that Soma is not buying that shelf space or funding the customer marketing. The partner does that. Sonoma just manufactures. The third is its own branded portfolio led by really facing its itch burn rash and pain hydrogel which picked up the national psoriasis foundation seal of recognition in 2025. Soma holds 23 FDA 510k clearances plus registrations across the markets it sells into. to a partner that portfolio is the product. A brand that wants an HOCCI wound care line can spend years and serious money building its own regulatory file or it can work with the company that already has the clearance and the validated plant. And Soma treats that portfolio as something it keeps invested in rather than something it finished. On June 30th of this year, it landed a new clearance for its micro DCN wound irrigation solution. Now, of course, this is a super small cap company with extreme risks and you got to make sure that you're doing your own due diligence. Most small companies fail and this is a very capital-intensive space which means dilution is a very high likelihood over time. But anyh who the story with Sonoma is that it is a small company sitting on a molecule with with a potential scientific edge over what most of the market currently uses and on a stabilization process and regulatory portfolio that took 20 years to build and would take a competitor about as long to match. This past year revenue grew 37%. US revenue more than doubled. The ibat loss narrowed by 38% and the fourth quarter came within a couple hundred,000 of breaking even on that measure. The product is in CVS and Walmart, in Medines Hospital and Home Health Channels and in more than 55 countries. Anyways, go ahead and take a look at Sonoma Pharmaceuticals investor relations page linked down below. As always, make sure to do all of your own due diligence. This is a sponsored segment and this is not financial advice. Have a great rest of your day and we'll see you in the next